Bone health evaluation one year after aromatase inhibitors completion

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pineda-Moncusí, Marta
• dc.contributor.author Servitja Tormo, Sonia
• dc.contributor.author Casamayor, Guillem
• dc.contributor.author Cos, Maria Lourdes
• dc.contributor.author Rial, Abora
• dc.contributor.author Rodriguez-Morera, Jaime
• dc.contributor.author Tusquets Trias de Bes, Ignacio
• dc.contributor.author Díez Pérez, Adolfo
• dc.contributor.author Garcia Giralt, Natàlia
• dc.contributor.author Nogués Solan, Francesc Xavier
• dc.date.accessioned 2019-03-19T08:32:34Z
• dc.date.issued 2018
• dc.description.abstract Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The present study aimed to assess BMD changes one year after AI-therapy completion. METHODS: Data were collected from 864 postmenopausal women treated with AI during 5 years (5y-AI group), or during 2-3 years after taking tamoxifen therapy (pTAM-AI group). Participants with osteoporosis were treated with oral bisphosphonates (BP). BMD changes in lumbar spine (LS), femoral neck (FN) and total hip (TH) between baseline, end of treatment, and at one year post-treatment were assessed using repeated-measures ANOVA. RESULTS: At the end of AI-treatment, 382 patients had available BMD values and 316 also had post-treatment BMD values. As expected, BMD levels were decreased at AI-completion in non-BP treated patients. After one year, LS BMD increased in both groups (5y-AI: +2.11% [95%CI: 1.55 to 2.68], p < 0.001; pTAM-AI: +1.00% [95%CI: 0.49 to 1.51], p < 0.001) compared with the end of AI-therapy, while values at FN and TH remained stable. On the other hand, BMD values of BP-treated patients were increased or maintained at the end of AI-treatment and also at post-treatment. CONCLUSIONS: At one year after AI-completion, FN and TH BMD remained reduced in non-BP treated women, while LS BMD was recovered in the 5y-AI group and partially recovered in the pTAM-AI group. BP treatment increased or maintained BMD values at the end of therapy and at one year post-treatment.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pineda-Moncusí M, Servitja S, Casamayor G, Cos ML, Rial A, Rodriguez-Morera J. et al. Bone health evaluation one year after aromatase inhibitors completion. Bone. 2018 Dec;117:54-59. DOI: 10.1016/j.bone.2018.09.010
• dc.identifier.doi http://dx.doi.org/10.1016/j.bone.2018.09.010
• dc.identifier.issn 1873-2763
• dc.identifier.uri http://hdl.handle.net/10230/36862
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Bone. 2018 Dec;117:54-9
• dc.rights © Elsevier http://dx.doi.org/10.1016/j.bone.2018.09.010
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Bone mineral density
• dc.subject.keyword Aromatase inhibitors
• dc.subject.keyword B-ABLE cohort
• dc.subject.keyword Bisphosphonates
• dc.subject.keyword Breast cancer
• dc.subject.other Ossos -- Malalties
• dc.subject.other Mama -- Càncer
• dc.title Bone health evaluation one year after aromatase inhibitors completion
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion